Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial

Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial

Author Mattar, Andre Autor UNIFESP Google Scholar
Logullo, Angela Flavia Autor UNIFESP Google Scholar
Facina, Gil Autor UNIFESP Google Scholar
Nonogaki, Suely Google Scholar
Soares, Fernando Augusto Google Scholar
Gebrim, Luiz Henrique Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Adolfo Lutz Inst
Antonio Prudente Fdn
Abstract The objective of this study was to compare Ki-67, Bcl-2, Bax, Bak, ER, and PgR expression in postmenopausal women with ER-positive invasive breast cancer (IBC) before and after short-term hormone therapy (HT) with either tamoxifen or anastrozole in order to identify a possible biomarker profile associated with hormone resistance.Fifty-eight patients with palpable IBC were assigned to receive neoadjuvant therapy with either anastrozole, placebo, or tamoxifen for 26 days prior to surgery. Tissue microarray blocks were constructed from pre- and post-treatment biopsy samples and used for immunohistochemical analysis. Biomarker (Ki-67, Bcl-2, Bax, Bak, ER, and PgR) levels were assessed semiquantitatively using the Allred score. A statistical analysis was performed using general estimating equations (GEE) and analysis of variance (ANOVA) with a significance level of 0.05.There was a significant reduction in PgR scores from baseline (mean, 4.22) to post-treatment (mean, 1.94) in the anastrozole group, but only a non-significant trend toward an increase in PgR scores was found in the tamoxifen group. There was a significant reduction in Ki-67 scores from baseline (mean, 3.61) to post-treatment (mean, 2.56) in the anastrozole group (P = 0.01), but only a non-significant trend toward a reduction in Ki-67 scores was found in the tamoxifen group.There was a significant reduction in PgR and Ki-67 expression in the group treated with anastrozole. in the present study, the short-term HT was not associated with changes in apoptosis-related protein levels, regardless the type of drug used.
Keywords Anastrozole
Breast cancer
Ki-67
Estrogen receptor
Progesterone receptor
Short-term hormone therapy
Language English
Date 2011-05-01
Published in Journal of Cancer Research and Clinical Oncology. New York: Springer, v. 137, n. 5, p. 897-905, 2011.
ISSN 0171-5216 (Sherpa/Romeo, impact factor)
Publisher Springer
Extent 897-905
Origin http://dx.doi.org/10.1007/s00432-010-0950-4
Access rights Closed access
Type Article
Web of Science ID WOS:000289440900017
URI http://repositorio.unifesp.br/handle/11600/33664

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account